Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

The prognosis for patients multiple myeloma (MM) has improved substantially over the past
decade with the development of new, more effective chemotherapeutic agents and regimens …

Background Hereditary hemorrhagic telangiectasia (HHT) is characterized by extensive
telangiectasias and arteriovenous malformations. The primary clinical manifestation is …

Background Few effective treatments exist for patients with refractory or relapsed and
refractory multiple myeloma not responding to treatment with bortezomib and lenalidomide …

This multicenter, open-label, randomized phase 2 study assessed the efficacy and safety of
pomalidomide (POM) with/without low-dose dexamethasone (LoDEX) in patients with …

Abstract Treatment in medical oncology is gradually shifting from the use of nonspecific
chemotherapeutic agents toward an era of novel targeted therapy in which drugs and their …

The approach to the patient with relapsed or relapsed/refractory multiple myeloma (RRMM)
requires a careful evaluation of the results of previous treatments, the toxicities associated …

Background We aimed to assess efficacy and tolerability of vorinostat in combination with
bortezomib for treatment of patients with relapsed or refractory multiple myeloma. Methods In …

Pomalidomide and low-dose dexamethasone (PomDex) is standard treatment of
lenalidomide refractory myeloma patients who have received> 2 prior therapies. We aimed …

The combination of pomalidomide (POM) and dexamethasone (DEX) was evaluated for
relapsed/refractory primary central nervous system lymphoma (PCNSL) and primary …